

Stephen Mitchell

1. Dalal MR, Mitchell SA, McClosky C, Zagadailov EA, Gautam A. Epidemiological and humanistic burden of cutaneous T-cell lymphomas: results of a systematic review. *Hematol Oncol*. 2017 35(Suppl S2):389-90.
2. Mitchell S, Manounah L, Liedgens H, Johannes E. AB0896 The effect of serum uric acid levels on tophus status and flares in patients with gout: a systematic review. *Ann Rheum Dis*. 2017;76:1369-70.
3. Mitchell S, Liedgens H, Johannes E. Mortality in patients with gout: a systematic review. *Ann Rheum Dis*. 2017;76(Suppl 2):THU0462.
4. Kitchen H, Aldhouse N, Trigg A, Palencia R, Mitchell S. A review of patient-reported outcome measures to assess female infertility-related quality of life. *Health Qual Life Outcomes*. 2017;15(1):86.
5. Dalal MR, Mitchell SA, McClosky C, Zagadailov EA, Gautam A. Long-term quality of life in patients with advanced Hodgkin lymphoma: a systematic review. *Hematol Oncol*. 2017;35(Suppl S2):311-2.
6. Burton HE, Mitchell SA, Watt M. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for *Clostridium difficile* Infection. *Pharmacoeconomics*. 2017.
7. Batson S, Mitchell SA, Windisch R, Damonte E, Munk VC, Reguart N. Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. *Onco Targets Ther*. 2017;10:2473-82.
8. Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. *J Hosp Infect*. 2017;96(1):1-15.
9. Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. *Int J Cardiol*. 2016;204:88-94.
10. Kitchen H, Aldhouse NV, Trigg A, Palencia R, Mitchell S. A review of patient-reported outcome measures to assess infertility-related quality of life. *Value Health*. 2016;19(7):A404.
11. Gielen V, Alexopoulos S, Hudson P, Mitchell S. Health State Utilities in chronic heart failure in the UK: a systematic review. *Value Health*. 2016;19(7):A657.
12. Gielen V, Alexopoulos S, Hudson P, Mitchell S. Resource use in chronic heart failure in the UK: a systematic review. *Value Health*. 2016;19(7):A662.
13. Cohen AT, Hamilton M, Bird A, Mitchell SA, Li X, Horblyuk R, et al. Correction: Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. *PLoS One*. 2016;11(9):e0163386.
14. Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, et al. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. *PLoS One*. 2016;11(8):e0160064.
15. Burton H, Mitchell SA, Watt M. The cost-effectiveness of treatments for *Clostridium difficile* infection: a systematic review. *Value Health*. 2016;19(3):A218.
16. Mitchell SA, Paine A, Moffatt M, Neale TA, Orme ME, Hawes C. Comparison of Bazedoxifene/Conjugated Oestrogens Vs Current Therapies in the Treatment of Postmenopausal Symptoms: Systematic Review and Meta-Analysis. *Value Health*. 2015;18(7):A733.
17. Liepa AM, Mitchell S, Batson S, Jen MH, Davie A, Taipale KL, et al. Systematic review and meta-analysis of recommended second-line therapies for advanced gastric cancer (GC). *Eur J Cancer*. 2015;51(3):s437.
18. Larkin J, Paine A, Foley G, Mitchell S, Chen C. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. *Expert Opin Pharmacother*. 2015;16(13):1915-27.

19. King D, Mitchell S, Dillon R, Lockhart I. The value of non-randomised evidence for informing clinical effectiveness: an assessment of HTA requirements and published guidance regarding the appropriateness of non-randomised data. *Value Health*. 2015;18(3):A89.
20. Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, et al. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. *PLoS One*. 2015;10(12):e0144856.
21. Cohen AT, Batson S, Hamilton M, Masseria C, Mitchell S, Phatak H. Comparison Of Apixaban, Dabigatran, Rivaroxaban, And Edoxaban In The Acute Treatment And Prevention Of Venous Thromboembolism: Systematic Review And Network Meta-Analysis. *Value Health*. 2015;18(3):A132.
22. Cohen A, Batson S, Hamilton M, Masseria C, Mitchell S, Phatak H. Comparison of oral anticoagulants or antiplatelet therapy for the extended treatment of venous thromboembolism: systematic review and network meta-analysis. *J Am Coll Cardiol*. 2015;65(10S):A2086.
23. Carter GC, King DT, Hess LM, Mitchell SA, Taipale KL, Kiiskinen U, et al. Health state utility values associated with advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma: a systematic review. *J Med Econ*. 2015;18(11):954-66.
24. Valle JW, Eatock M, Clueit B, Gabriel Z, Ferdinand R, Mitchell S. A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. *Cancer Treat Rev*. 2014;40(3):376-89.
25. Patel A, King D, Greenall G, Mitchell SA, Purushotham S, Hudson PM. The selection of appropriate health state utility values (HSUVs) for Health Technology Assessment (HTA): lessons to be learnt. *Value Health*. 2014;17(7):A573.
26. King DT, Trautmann M, Sabater J, Pahor A, Shaw JW, Grandy S, et al. Relevance of clinical trials to inform HTA: disparity between HTA evidence requirements and published RCTs in type 2 diabetes mellitus. *Value Health*. 2014;17(3):A263.
27. King D, Mitchell SA, Keyzor I, Kiri S. Systematic Review of Societal Cost of Illness Evidence in Patients With Psoriatic Arthritis. *Value Health*. 2014;17(7):A378.
28. King D, Mitchell SA, Keyzor I, Kiri S. Systematic Review of Societal Cost of Illness Evidence in Patients With Ankylosing Spondylitis. *Value Health*. 2014;17(7):A378.
29. Cuyun Cater G, King DT, Mitchell SA, Hess LM, Taipale U, Kiiskien N, et al. A systematic review of health-state utility values in advanced gastric, oesophageal, or gastro-oesophageal junction adenocarcinoma. *Value Health*. 2014;17(3):A92.
30. Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. *BMC Musculoskelet Disord*. 2014;15:26.
31. Batson S, Mitchell SA, King D. The use and acceptance of novel statistical analyses to support technology submissions to HTA authorities. *Value Health*. 2014;17(7):A576-A7.
32. Sullivan SD, Orme ME, Morais E, Mitchell SA. Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis. *Int J Cardiol*. 2013;165(2):229-36.
33. Rao N, Liu X, Clafin AB, Phatak H, Mitchell SA. Quality of life in patients with venous thromboembolism: a systematic literature review. *Value Health*. 2013;16:PCV122.
34. Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. *Clin Appl Thromb Hemost*. 2013;19(6):619-31.
35. Liu X, Phatak H, Dillon R, Mitchell SA. Epidemiology and mortality of venous thromboembolism across patient populations: a systematic literature review. *Value Health*. 2013;16(3):A272.
36. Larkin J, Paine A, Tumor I, Cappelleri JC, Healey PJ, Sr., Foley G, et al. Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis. *Expert Opin Pharmacother*. 2013;14(1):27-39.
37. Garcia-Stewart S, Mitchell SA. Mothers' own milk for the feeding of preterm infants: a systematic literature review. *Value Health*. 2013;16(7):A330.
38. Clafin AB, Mitchell CR, Liu X, Phatak H, Mitchell SA. Economic burden of venous thromboembolism across patient populations: a literature review. *Value Health*. 2013;16(7):A519.

39. Spurden D, Orme M, Mitchell S, Bird A. Systematic review and network meta-analysis of biological therapy for the management of active psoriatic arthritis *Ann Rheum Dis*. 2012;71(Suppl 3):SAT0298.
40. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. *Biologics*. 2012;6:429-64.
41. Ferdinand R, Mitchell SA, Batson S, Tumor I. Treatments for chronic myeloid leukemia: a qualitative systematic review. *J Blood Med*. 2012;3:51-76.
42. Cohen A, Drost P, Marchant N, Mitchell S, Orme M, Rublee D, et al. The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. *Clin Appl Thromb Hemost*. 2012;18(6):611-27.
43. Svensson A, Chambers C, Ganemo A, Mitchell SA. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. *Curr Med Res Opin*. 2011;27(7):1395-406.
44. Orme ME, Fotheringham I, Mitchell SA, Spurden D, Bird A, editors. Systematic review and network meta-analysis of combination therapy for methotrexate-experienced, rheumatoid arthritis patients: Analysis of American College of Rheumatology criteria scores 20, 50 and 70 (ACR 20/50/70). ACR/ARHP Scientific Meeting; 2011; Chicago, USA.
45. Lockhart IA, Orme ME, Mitchell SA. The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis. *Dement Geriatr Cogn Dis Extra*. 2011;1(1):212-27.
46. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. *Europace*. 2011;13(3):329-45.
47. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. *Semin Arthritis Rheum*. 2011;41(3):335-45 e6.
48. Orme M, Mitchell S, Lockhart I, Collins S. The efficacy of donepezil and memantine for treating behavioural and psychological symptoms of dementia (BPSD) in patients with Alzheimer's disease: systematic review and meta-analysis. *Value Health*. 2010;13(7):A445.
49. Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, et al. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review. *J Alzheimers Dis*. 2010;22(1):205-24.
50. Sullivan SD, Orme ME, Morais E, Mitchell S. A systematic review and meta-analysis of randomised clinical trials reviewing antiarrhythmic drugs for the treatment of atrial fibrillation. *Value Health*. 2009;12(7).
51. Mitchell S, Orme M, Eckert L, Reynolds M. The effect of anti-arrhythmic drug therapy on all-cause and cardiovascular mortality in atrial fibrillation patients: a systematic review and meta-analysis. *Value Health*. 2009;12(7):A316.
52. Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. *Dement Geriatr Cogn Disord*. 2009;28(5):389-403.
53. Lockhart I, Mitchell S, Kelly S. A systematic review of the real-world study evidence comparing the safety and tolerability of donepezil, rivastigmine and galantamine for the treatment of mild to moderate Alzheimer Disease. *Value Health*. 2009;12(7):A350-1.
54. Choy E, Marshall D, Gabriel Z, Mitchell S, Gylee E, Dakin HA. A systematic review and mixed treatment comparison (MTC) of the efficacy of pharmacological treatments for fibromyalgia. *Value Health*. 2009;12(7):A434.
55. Svensson A, Ganemo A, Chambers C, Mitchell S. Topical tacrolimus for the treatment of atopic dermatitis: a systematic review with meta-analysis. *Value Health*. 2008;11(6):A616.

56. Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, et al. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a German perspective. *Clin Drug Investig*. 2008;28(9):583-601.
57. Sedelnikova OA, Nakamura A, Kovalchuk O, Koturbash I, Mitchell SA, Marino SA, et al. DNA double-strand breaks form in bystander cells after microbeam irradiation of three-dimensional human tissue models. *Cancer Res*. 2007;67(9):4295-302.
58. Moore SR, Marsden S, Macdonald D, Mitchell S, Folkard M, Michael B, et al. Genomic instability in human lymphocytes irradiated with individual charged particles: involvement of tumor necrosis factor alpha in irradiated cells but not bystander cells. *Radiat Res*. 2005;163(2):183-90.
59. Belyakov OV, Mitchell SA, Parikh D, Randers-Pehrson G, Marino SA, Amundson SA, et al. Biological effects in unirradiated human tissue induced by radiation damage up to 1 mm away. *Proc Natl Acad Sci U S A*. 2005;102(40):14203-8.
60. Mitchell SA, Randers-Pehrson G, Brenner DJ, Hall EJ. The bystander response in C3H 10T1/2 cells: the influence of cell-to-cell contact. *Radiat Res*. 2004;161(4):397-401.
61. Mitchell SA, Marino SA, Brenner DJ, Hall EJ. Bystander effect and adaptive response in C3H 10T(1/2) cells. *Int J Radiat Biol*. 2004;80(7):465-72.
62. Kadhim MA, Marsden S, Macdonald DA, Goodhead DT, Mitchell S, Folkard M, et al. Bystander-mediated genomic instability in human lymphocytes after single alpha-particle irradiation. *Radiat Res*. 2004;161:110-1.
63. Trochu JN, Dillon R, Gustafsson F, Mitchell SA, Mitrovic V, Alfieri O. Mitral regurgitation - Unmet need for improved management strategies. *Int J Cardiol Heart Vasc*. 2014;5:26-41.
64. Dalal MR, Mitchell S, McClosky C, Zagadailov E, Gautam A. Is Durability of Response Reported in Refractory CTCL: A Systematic Review. *Blood*. 2017;130(Suppl1):5598.
65. Dalal MR, Mitchell S, McClosky C, Zagadailov E, Gautam A. The Risk-Benefit Balance of Treatments for Hodgkin Lymphoma Reported in the Randomised and Non-Randomised Trial Setting: A Systematic Review. *Blood*. 2017;130(Suppl1):5605.